Appropriateness to set a group health based guidance value for nivalenol and its modified forms

Helle Katrine Knutsen, Lars Barregård, Margherita Bignami, Beat Brüschweiler, Sandra Ceccatelli, Bruce Cottrill, Michael Dinovi, Lutz Edler, Bettina Grasl-Kraupp, Christer Hogstrand, Laurentius (Ron) Hoogenboom, Carlo Stefano Nebbia, Isabelle P Oswald, Annette Petersen, Martin Rose, Alain-Claude Roudot, Tanja Schwerdtle, Christiane Vleminckx, Günter Vollmer, Heather Wallace & 8 others Chiara Dall'Asta, Arno C Gutleb, Manfred Metzler, Dominique Parent-Massin, Marco Binaglia, Hans Steinkellner, Jan Alexander, EFSA Panel on Contaminants in the Food Chain (CONTAM)

Research output: Contribution to journalArticle

3 Downloads (Pure)

Abstract

The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol since the previous opinion on nivalenol published in 2013, but as no new relevant data were identified the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 ?g/kg body weight (bw) established on bases of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 ?g/kg bw was established based on acute emetic events in mink. The only phase I metabolite of NIV identified is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc). DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals amounting up to about 50% of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it would rather overestimate than underestimate any risk.
Original languageEnglish
Article numbere04751
Number of pages25
JournalEFSA Journal
Volume15
Issue number4
Early online date19 Apr 2017
DOIs
Publication statusPublished - Apr 2017

Fingerprint

Health
Glucosides
No-Observed-Adverse-Effect Level
nivalenol
Body Weight
Emetics
Mink
Food Chain
Poisons
Uncertainty

Keywords

  • nivalenol
  • modified forms
  • group health based guidance value

Cite this

Knutsen, H. K., Barregård, L., Bignami, M., Brüschweiler, B., Ceccatelli, S., Cottrill, B., ... EFSA Panel on Contaminants in the Food Chain (CONTAM) (2017). Appropriateness to set a group health based guidance value for nivalenol and its modified forms. EFSA Journal, 15(4), [e04751]. https://doi.org/10.2903/j.efsa.2017.4751

Appropriateness to set a group health based guidance value for nivalenol and its modified forms. / Knutsen, Helle Katrine; Barregård, Lars; Bignami, Margherita; Brüschweiler, Beat; Ceccatelli, Sandra; Cottrill, Bruce; Dinovi, Michael; Edler, Lutz; Grasl-Kraupp, Bettina; Hogstrand, Christer; Hoogenboom, Laurentius (Ron); Nebbia, Carlo Stefano; Oswald, Isabelle P; Petersen, Annette; Rose, Martin; Roudot, Alain-Claude; Schwerdtle, Tanja; Vleminckx, Christiane; Vollmer, Günter; Wallace, Heather; Dall'Asta, Chiara; Gutleb, Arno C; Metzler, Manfred; Parent-Massin, Dominique; Binaglia, Marco; Steinkellner, Hans; Alexander, Jan; EFSA Panel on Contaminants in the Food Chain (CONTAM).

In: EFSA Journal, Vol. 15, No. 4, e04751, 04.2017.

Research output: Contribution to journalArticle

Knutsen, HK, Barregård, L, Bignami, M, Brüschweiler, B, Ceccatelli, S, Cottrill, B, Dinovi, M, Edler, L, Grasl-Kraupp, B, Hogstrand, C, Hoogenboom, LR, Nebbia, CS, Oswald, IP, Petersen, A, Rose, M, Roudot, A-C, Schwerdtle, T, Vleminckx, C, Vollmer, G, Wallace, H, Dall'Asta, C, Gutleb, AC, Metzler, M, Parent-Massin, D, Binaglia, M, Steinkellner, H, Alexander, J & EFSA Panel on Contaminants in the Food Chain (CONTAM) 2017, 'Appropriateness to set a group health based guidance value for nivalenol and its modified forms', EFSA Journal, vol. 15, no. 4, e04751. https://doi.org/10.2903/j.efsa.2017.4751
Knutsen HK, Barregård L, Bignami M, Brüschweiler B, Ceccatelli S, Cottrill B et al. Appropriateness to set a group health based guidance value for nivalenol and its modified forms. EFSA Journal. 2017 Apr;15(4). e04751. https://doi.org/10.2903/j.efsa.2017.4751
Knutsen, Helle Katrine ; Barregård, Lars ; Bignami, Margherita ; Brüschweiler, Beat ; Ceccatelli, Sandra ; Cottrill, Bruce ; Dinovi, Michael ; Edler, Lutz ; Grasl-Kraupp, Bettina ; Hogstrand, Christer ; Hoogenboom, Laurentius (Ron) ; Nebbia, Carlo Stefano ; Oswald, Isabelle P ; Petersen, Annette ; Rose, Martin ; Roudot, Alain-Claude ; Schwerdtle, Tanja ; Vleminckx, Christiane ; Vollmer, Günter ; Wallace, Heather ; Dall'Asta, Chiara ; Gutleb, Arno C ; Metzler, Manfred ; Parent-Massin, Dominique ; Binaglia, Marco ; Steinkellner, Hans ; Alexander, Jan ; EFSA Panel on Contaminants in the Food Chain (CONTAM). / Appropriateness to set a group health based guidance value for nivalenol and its modified forms. In: EFSA Journal. 2017 ; Vol. 15, No. 4.
@article{87e7eb7f58094d87bfe3b4c64385d30e,
title = "Appropriateness to set a group health based guidance value for nivalenol and its modified forms",
abstract = "The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol since the previous opinion on nivalenol published in 2013, but as no new relevant data were identified the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 ?g/kg body weight (bw) established on bases of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 ?g/kg bw was established based on acute emetic events in mink. The only phase I metabolite of NIV identified is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc). DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals amounting up to about 50{\%} of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it would rather overestimate than underestimate any risk.",
keywords = "nivalenol, modified forms, group health based guidance value",
author = "Knutsen, {Helle Katrine} and Lars Barreg{\aa}rd and Margherita Bignami and Beat Br{\"u}schweiler and Sandra Ceccatelli and Bruce Cottrill and Michael Dinovi and Lutz Edler and Bettina Grasl-Kraupp and Christer Hogstrand and Hoogenboom, {Laurentius (Ron)} and Nebbia, {Carlo Stefano} and Oswald, {Isabelle P} and Annette Petersen and Martin Rose and Alain-Claude Roudot and Tanja Schwerdtle and Christiane Vleminckx and G{\"u}nter Vollmer and Heather Wallace and Chiara Dall'Asta and Gutleb, {Arno C} and Manfred Metzler and Dominique Parent-Massin and Marco Binaglia and Hans Steinkellner and Jan Alexander and {EFSA Panel on Contaminants in the Food Chain (CONTAM)}",
note = "The Panel wishes to thank the members of the Working Group on HBGV for mycotoxins and their modified forms: Jan Alexander, Chiara Dall'Asta, Arno Gutleb, Manfred Metzler, Isabelle P Oswald and Dominique Parent‐Massin for the preparatory work on this scientific output, and the EFSA staff members: Marco Binaglia and Hans Steinkellner for the support provided to this scientific output. Adopted: 15 March 2017",
year = "2017",
month = "4",
doi = "10.2903/j.efsa.2017.4751",
language = "English",
volume = "15",
journal = "EFSA Journal",
issn = "1831-4732",
publisher = "John Wiley & Sons, Ltd",
number = "4",

}

TY - JOUR

T1 - Appropriateness to set a group health based guidance value for nivalenol and its modified forms

AU - Knutsen, Helle Katrine

AU - Barregård, Lars

AU - Bignami, Margherita

AU - Brüschweiler, Beat

AU - Ceccatelli, Sandra

AU - Cottrill, Bruce

AU - Dinovi, Michael

AU - Edler, Lutz

AU - Grasl-Kraupp, Bettina

AU - Hogstrand, Christer

AU - Hoogenboom, Laurentius (Ron)

AU - Nebbia, Carlo Stefano

AU - Oswald, Isabelle P

AU - Petersen, Annette

AU - Rose, Martin

AU - Roudot, Alain-Claude

AU - Schwerdtle, Tanja

AU - Vleminckx, Christiane

AU - Vollmer, Günter

AU - Wallace, Heather

AU - Dall'Asta, Chiara

AU - Gutleb, Arno C

AU - Metzler, Manfred

AU - Parent-Massin, Dominique

AU - Binaglia, Marco

AU - Steinkellner, Hans

AU - Alexander, Jan

AU - EFSA Panel on Contaminants in the Food Chain (CONTAM)

N1 - The Panel wishes to thank the members of the Working Group on HBGV for mycotoxins and their modified forms: Jan Alexander, Chiara Dall'Asta, Arno Gutleb, Manfred Metzler, Isabelle P Oswald and Dominique Parent‐Massin for the preparatory work on this scientific output, and the EFSA staff members: Marco Binaglia and Hans Steinkellner for the support provided to this scientific output. Adopted: 15 March 2017

PY - 2017/4

Y1 - 2017/4

N2 - The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol since the previous opinion on nivalenol published in 2013, but as no new relevant data were identified the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 ?g/kg body weight (bw) established on bases of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 ?g/kg bw was established based on acute emetic events in mink. The only phase I metabolite of NIV identified is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc). DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals amounting up to about 50% of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it would rather overestimate than underestimate any risk.

AB - The EFSA Panel on Contaminants in the Food Chain (CONTAM) reviewed new studies on nivalenol since the previous opinion on nivalenol published in 2013, but as no new relevant data were identified the tolerable daily intake (TDI) for nivalenol (NIV) of 1.2 ?g/kg body weight (bw) established on bases of immuno- and haematotoxicity in rats was retained. An acute reference dose (ARfD) of 14 ?g/kg bw was established based on acute emetic events in mink. The only phase I metabolite of NIV identified is de-epoxy-nivalenol (DE-NIV) and the only phase II metabolite is nivalenol-3-glucoside (NIV3Glc). DE-NIV is devoid of toxic activity and was thus not further considered. NIV3Glc can occur in cereals amounting up to about 50% of NIV. There are no toxicity data on NIV3Glc, but as it can be assumed that it is hydrolysed to NIV in the intestinal tract it should be included in a group TDI and in a group ARfD with NIV. The uncertainty associated with the present assessment is considered as high and it would rather overestimate than underestimate any risk.

KW - nivalenol

KW - modified forms

KW - group health based guidance value

U2 - 10.2903/j.efsa.2017.4751

DO - 10.2903/j.efsa.2017.4751

M3 - Article

VL - 15

JO - EFSA Journal

JF - EFSA Journal

SN - 1831-4732

IS - 4

M1 - e04751

ER -